• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/12/25 7:10:31 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    8-K
    false000176844600017684462025-08-122025-08-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 12, 2025

     

     

    Climb Bio, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40708

    83-2273741

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    20 William Street

    Suite 145

     

    Wellesley Hills, Massachusetts

     

    02481

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (866) 857-2596

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CLYM

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 12, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

    99.1

    Press release of Climb Bio, Inc., dated August 12, 2025

     104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Climb Bio, Inc.

     

     

     

     

    Date:

    August 12, 2025

    By:

    /s/ Aoife Brennan

     

     

     

    Aoife Brennan, M.B., Ch.B.
    President and Chief Executive Officer

     


    Get the next $CLYM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    8/15/2025$9.00Outperform
    Robert W. Baird
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    SEC Filings

    View All

    SEC Form 10-Q filed by Climb Bio Inc.

    10-Q - Climb Bio, Inc. (0001768446) (Filer)

    8/12/25 7:15:52 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    8/12/25 7:10:31 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Climb Bio Inc.

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    6/18/25 7:08:36 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas Stephen Basil was granted 100,375 shares, increasing direct ownership by 49% to 304,657 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    8/11/25 4:15:08 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Brennan Aoife converted options into 68,750 shares and sold $25,154 worth of shares (20,618 units at $1.22) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    7/1/25 4:37:17 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Stephen Basil converted options into 25,094 shares, increasing direct ownership by 14% to 204,282 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    7/1/25 4:32:24 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Robert W. Baird initiated coverage on Climb Bio with a new price target

    Robert W. Baird initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $9.00

    8/15/25 8:18:48 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Climb Bio with a new price target

    Oppenheimer initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

    6/6/25 8:35:04 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Climb Bio with a new price target

    BTIG Research initiated coverage of Climb Bio with a rating of Buy and set a new price target of $7.00

    5/22/25 8:24:05 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies; Phase 1 Trial Expected to Initiate in the Coming Weeks, with Initial Data Anticipated in First Half 2026 CLYM116 Focused Webcast Event, Including New Preclinical Data, Planned for September 2025; IND or CTA Submission for IgA Nephropathy (IgAN) Expected in Second Half 2025 Edgar D. Charles, M.D., MSc Appointed Chief Medical Officer Strong Financial Position,

    8/12/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an ex

    5/19/25 4:34:52 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

    WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

    2/24/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

    SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

    11/14/24 9:29:34 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care